GOTHENBURG, Sweden, Oct. 16, 2024 /PRNewswire/ — SKF will publish its Q3 results for 2024 on 30 October at approximately 07:00 (CET).

Investors, analysts and media are invited to join a webcast, which will be held in English, at 08:00 (CET).

To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers: Link to web event: https://www.investis-live.com/skf/6703fe36b2cedb000e390899/aherus  Sweden: +46 8 5051 0031 UK / International: +44 207 107 0613

All information regarding the results will be made available on the Group’s IR website: https://investors.skf.com/en/quarterly-reports

Media: To book interviews with Rickard Gustafson, President and CEO, or Niclas Rosenlew, CFO, after the webcast, please contact Carl Bjernstam on carl.bjernstam@skf.com.

Aktiebolaget SKF      (publ)

For further information, please contact:PRESS: Carl Bjernstam, Head of Media Relationstel: 46 31-337 2517; mobile: 46 722-201 893; e-mail: carl.bjernstam@skf.comINVESTOR RELATIONS: Sophie Arnius, Head of Investor Relationstel: 46 31-337 8072; mobile: 46 705-908 072; e-mail: sophie.arnius@skf.com

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/skf/r/skf-to-publish-q3-report-on-30-october,c4051570

The following files are available for download:

https://mb.cision.com/Main/637/4051570/3055428.pdf

20241016 SKF to publish Q3 report on 30 October

https://news.cision.com/skf/i/skf-ceramic-bearing,c3342539

SKF Ceramic Bearing

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

E-POWER leads global market innovation with LED power supplies

SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ — E-POWER CO.,LTD, a company…

NYSE Content Update: FIRY Announces Rebranding From Skillz Inc.

NYSE issues a pre-market daily advisory direct from the trading floor. NEW…

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Vertex obtains an exclusive license to TreeFrog’s C-StemTM  manufacturing technology in type 1…